BOSTON – Among the data presented at the joint Molecular Targets meeting of the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) were phase I trial as well as preclinical results for the newest member of the a poly-ADP ribose polymerase (PARP) inhibitor club.